Drug discovery programs boosted

December 03, 2010

Dec 03, 2010, Seoul, S. Korea - Institut Pasteur Korea (IP-K) has signed an agreement with sanofi-aventis Research & Development of Toulouse, France to continue research on the identification of new medicines.

The new contract, extending an agreement drawn up in the fall of 2009, illustrates the value of IP-K's PhenomicScreen™ to the pharmaceutical industry. The technology platform will be used to pinpoint active, non-toxic agents in sanofi-aventis' proprietary chemical compound library.

The high-throughput, high-content visual screening approach of PhenomicScreen™ is well suited to identifying lead compounds. Dr. Priscille Brodin of IP-K explains that "Our phenotypic approach does not rely on a predefined target, but rather simultaneously selects both chemical compounds and an unknown cellular target solely by the clearly discernible effect on the disease model". The advantage, according to IP-K's Dr. Jonathan Cechetto, is that "The process has the ability to select novel targets, and only those which are functionally significant in the disease process".

Commenting on the new agreement with sanofi-aventis, Laurent Fraisse, director of infectious diseases research said "Over the past year the collaboration has made important strides in identifying potential new drugs, and we are pleased to extend our agreement with IP-K."

Center Director of Core Technologies of Institut Pasteur Korea Dr. Veronica Soloveva believes that the agreement is a vindication of the institute's innovative approach to drug discovery. "Phenomic technology increases the accuracy and speed of drug discovery", she said, "And we are delighted to be working with sanofi-aventis to accelerate their identification of new compounds".
-end-
About PhenomicScreen™

Institut Pasteur Korea has established core competence in PhenomicScreen™, a proprietary and advantageous phenotype based screening technology. This exclusive target free approach combines novel imaging technologies with tailor made high content and high throughput visual screens that reflect specific disease physiologies and enable the assessment of biological events live and in real time. In essence, our core platform technology allows for the cell itself to identify the most effective drug target out of the many complex molecular interactions underlying the development of a given disease. Confirmation of successful hits is followed by lead optimization and preclinical studies; the whole process being completed in as little as 18 months. In summary, this innovative core competence allows new therapeutic drugs to be identified faster and more reliably.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops, and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT PARIS: SAN) and in New York (NYSE: SNY).

About Institut Pasteur Korea

Institut Pasteur Korea is a non-profit organization based in South Korea. It was founded in April, 2004 with the strategic focus of enabling technologies and therapeutic development in disease models pertaining to public health. For additional information please visit http://www.ip-korea.org.

Institut Pasteur Korea

Related Drug Discovery Articles from Brightsurf:

December special issue of SLAS Discovery features 'drug discovery targeting COVID-19'
The December edition of SLAS Discovery, ''Drug Discovery Targeting COVID-19'' is a special collection assembled by Associate Editor Timothy Spicer (Scripps, FL, USA), focusing on drug discovery efforts toward the current global pandemic of COVID-19caused by the novel coronavirus, SARS-CoV-2.

New cell profiling method could speed TB drug discovery
A new cell profiling technology combines high throughput imaging and machine learning to provide a rapid, cost-effective way to determine how specific compounds act to destroy the bacterium that causes tuberculosis.

An open-access tool to accelerate drug discovery
The Chemical Checker provides processed, harmonized and ready-to-use bioactivity information on more than 1M small molecules.

New macrolactone database could aid drug discovery, research
Researchers have created a free-to-use database of 14,000 known macrolactones -- large molecules used in drug development -- which contains information about the molecular characteristics, chemical diversity and biological activities of this structural class.

Discovery of a drug to rescue winter depression-like behavior
A group of animal biologists and chemists at the Institute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, has used a chemical genomics approach to explore the underlying mechanism of winter depression-like behavior and identified a drug that rescues winter depression-like behavior in medaka fish.

Fat-fighting drug discovery
Cancer-fighting compound fights obesity and diabetes.

New cell models for ocular drug discovery
Researchers at the University of Eastern Finland have developed two new cell models that can open up new avenues for ocular drug discovery.

Machine learning's next frontier: Epigenetic drug discovery
Scientists at Sanford Burnham Prebys Medical Discovery Institute have developed a machine-learning algorithm that gleans information from microscope images -- allowing for high-throughput epigenetic drug screens that could unlock new treatments for cancer, heart disease, mental illness and more.

Discovery of how colorectal cancer drug works will help more patients
Some colorectal cancer patients with a certain gene mutation benefit from a chemotherapy drug called cetuximab, although the mechanism of how this drug worked was unknown.

Speeding up the drug discovery process to help patients
An international research team is perfecting a method to predict the potential clinical implications of new drugs before clinical trials even start.

Read More: Drug Discovery News and Drug Discovery Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.